Investigational dry eye treatment moves to next phase

Article

Alacrity Biosciences has announced positive results from a Phase II study of its treatment for dry eye, ALTY-0501.

Alacrity Biosciences has announced positive results from a Phase II study of its treatment for dry eye, ALTY-0501.

ALTY-0501 is a proprietary topical formulation of 0.025% doxycycline in a non-antimicrobial dose, which acts to inhibit matrix metalloproteinase-9 (MMP-9). By inhibiting MMP-9, ALTY-0501 is thought to prevent the disruption of the epithelial barrier on the ocular surface.

The Phase II double-masked, randomized, parallel-group study enrolled 160 subjects to assess the safety and efficacy of the drug. Patients with dry eye were exposed to a controlled adverse environment on day one and asked to self-administer ALTY-0501 eye drops or vehicle eye drops four times a day. Patients were re-exposed to the controlled adverse environment on days 28 and 56. Environmental damage was assessed using fluorescein staining and symptoms were measured daily through patient diaries throughout the study period.

Patients who received ALTY-0501 demonstrated statistically significantly lower scores after fluorescein staining, following exposure, than the control group on day 28 (p<0.05). The drug also demonstrated statistically significant advantages compared with vehicle in the patient diary scores. Specifically, patient diary scores reflected statistically significantly lower scores for the symptoms of burning (p<0.0001), stinging (p<0.0001) and grittiness (p<0.0001) in the active treatment group.

Alacrity plans to initiate Phase III trials early in 2008.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.